Please login to the form below
Urinary incontinence
This page shows the latest Urinary incontinence news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
Underwhelming results send shares down. Vivek Ramaswamy’s Roivant group hasn’t been able to chalk up many clinical successes, and a phase 3 win for its Urovant unit in urinary ... main efficacy measures in the study namely the number of daily urge
Latest news
-
The power of pharma businesses to drive social change
The condition is caused by prolonged labour and leads to faecal or urinary incontinence, or both.
-
Roivant gets $1.1bn investment from Japan's SoftBank
Urovant, launched in June, is taking a drug from Merck &Co called vibegron through late-stage development for urinary incontinence.
-
Allergan subsidiary fined $125m for illegal marketing
necessary. The medications involved in the claims are Asacol (mesalamine), Doryx (doxycycline hyclate), Enablex (darifenacin) for urinary incontinence, the hormone Estrace (estriadol) and the contraceptive Loestrin (ethinyl estradiol, norethindrone,
-
Ipsen strengthens neurology efforts with Syntaxin purchase
This includes Syntaxin's lead product candidate, senrebotase (AGN 214868) which is in phase II trials for several conditions, including post-herpetic neuralgia, idiopathic overactive bladder and urinary incontinence.
-
Allergan gets US approval for Botox in overactive bladder
OAB is a condition in which the bladder squeezes too often or squeezes without warning, leading to urinary incontinence, sudden urgent need to urinate and frequent urination. ... In trials, patients treated with Botox over a 12-week period experienced
More from news
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Case study: Action on Fistula
Working with Forster Communications it ran a strategic review and identified obstetric fistula, a condition caused by prolonged obstructed labour, leading to faecal or urinary incontinence or both.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Could femtech be the answer to the gender health gap?
Adherence to pelvic floor muscle training with or without vaginal spheres in women with urinary incontinence: a secondary analysis from a randomized trial. ... Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback
-
Femtech: Transforming the future of women's healthcare
Affecting an estimated one in three women, and costing the NHS £233 million every year, in the case of urinary incontinence (UI), Femtech solutions can, in the majority of cases, reduce
-
How marketers are balancing the changing trends in women's health
Accessed November 3, 2021. Price N, Dawood R, Jackson SR. Pelvic floor exercise for urinary incontinence: a systematic literature review. ... Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback for urinary
-
Can wearables really transform healthcare?
There was also a device for urinary incontinence which actually won the ‘Best of CES’ award for Digital Health and Fitness.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
